Lesson plan
XLR-12
XLR-12 is an indole-based synthetic cannabinoid drug that was invented by Abbott Laboratories in 2006. It is an analogue of XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB 2 receptor, with a K i of 0.09 nM and 167x selectivity over the related CB 1 receptor, however it still retains appreciable affinity for CB 1 with a K i of 15 nM.
Article summary
XLR-12 is an indole-based synthetic cannabinoid drug that was invented by Abbott Laboratories in 2006. It is an analogue of XLR-11 where the 5-fluoropentyl chain has been replaced with a 4,4,4-trifluorobutyl chain. XLR-12 is relatively highly selective for the CB 2 receptor, with a K i of 0.09 nM and 167x selectivity over the related CB 1 receptor, however it still retains appreciable affinity for CB 1 with a K i of 15 nM.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.